## C Roland Wolf

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5730968/publications.pdf

Version: 2024-02-01

39 papers

1,534 citations

<sup>394421</sup>
19
h-index

37 g-index

43 all docs 43 docs citations

43 times ranked 2817 citing authors

#	Article	IF	CITATIONS
1	Through a glass, darkly? HepaRG and HepG2 cells as models of human phase I drug metabolism. Drug Metabolism Reviews, 2022, 54, 46-62.	3.6	12
2	Nrf2 activation does not affect adenoma development in a mouse model of colorectal cancer. Communications Biology, 2021, 4, 1081.	4.4	1
3	Quantifying ERK activity in response to inhibition of the BRAFV600E-MEK-ERK cascade using mathematical modelling. British Journal of Cancer, 2021, 125, 1552-1560.	6.4	6
4	Glutathione-S-transferase P promotes glycolysis in asthma in association with oxidation of pyruvate kinase M2. Redox Biology, 2021, 47, 102160.	9.0	23
5	Application of hepatic cytochrome b/P450 reductase null (HBRN) mice to study the role of cytochrome b in the cytochrome P450-mediated bioactivation of the anticancer drug ellipticine. Toxicology and Applied Pharmacology, 2019, 366, 64-74.	2.8	2
6	Constitutive Androstane Receptor 1 is Constitutively Bound to Chromatin and 'Primed' for Transactivation in Hepatocytes. Molecular Pharmacology, 2019, 95, 97-105.	2.3	12
7	Discovery of common and rare genetic risk variants for colorectal cancer. Nature Genetics, 2019, 51, 76-87.	21.4	377
8	Drug-induced chromatin accessibility changes associate with sensitivity to liver tumor promotion. Life Science Alliance, 2019, 2, e201900461.	2.8	6
9	Identification of Novel Pathways of Osimertinib Disposition and Potential Implications for the Outcome of Lung Cancer Therapy. Clinical Cancer Research, 2018, 24, 2138-2147.	7.0	21
10	Cytochrome b 5 impacts on cytochrome P450-mediated metabolism of benzo[a]pyrene and its DNA adduct formation: studies in hepatic cytochrome b 5 /P450 reductase null (HBRN) mice. Archives of Toxicology, 2018, 92, 1625-1638.	4.2	26
11	Measuring <i>in vivo</i> responses to endogenous and exogenous oxidative stress using a novel haem oxygenase 1 reporter mouse. Journal of Physiology, 2018, 596, 105-127.	2.9	22
12	Interaction between polymorphisms in aspirin metabolic pathways, regular aspirin use and colorectal cancer risk: A case-control study in unselected white European populations. PLoS ONE, 2018, 13, e0192223.	2.5	5
13	Xenobiotic CAR Activators Induce Dlk1-Dio3 Locus Noncoding RNA Expression in Mouse Liver. Toxicological Sciences, 2017, 158, 367-378.	3.1	7
14	Novel Pathways of Ponatinib Disposition Catalyzed By CYP1A1 Involving Generation of Potentially Toxic Metabolites. Journal of Pharmacology and Experimental Therapeutics, 2017, 363, 12-19.	2.5	29
15	Progress in identifying epigenetic mechanisms of xenobiotic-induced non-genotoxic carcinogenesis. Current Opinion in Toxicology, 2017, 3, 62-70.	5.0	7
16	Application of Mice Humanized for CYP2D6 to the Study of Tamoxifen Metabolism and Drug–Drug Interaction with Antidepressants. Drug Metabolism and Disposition, 2017, 45, 17-22.	3.3	14
17	Loss of Tet1-Associated 5-Hydroxymethylcytosine Is Concomitant with Aberrant Promoter Hypermethylation in Liver Cancer. Cancer Research, 2016, 76, 3097-3108.	0.9	71
18	Cyp2c70 is responsible for the species difference in bile acid metabolism between mice and humans. Journal of Lipid Research, 2016, 57, 2130-2137.	4.2	221

#	Article	IF	Citations
19	Olaparib, Monotherapy or with Ionizing Radiation, Exacerbates DNA Damage in Normal Tissues: Insights from a New p21 Reporter Mouse. Molecular Cancer Research, 2016, 14, 1195-1203.	3.4	24
20	Aldo-keto reductases are biomarkers of NRF2 activity and are co-ordinately overexpressed in non-small cell lung cancer. British Journal of Cancer, 2016, 115, 1530-1539.	6.4	31
21	The Role of Protein-Protein and Protein-Membrane Interactions on P450 Function. Drug Metabolism and Disposition, 2016, 44, 576-590.	3.3	39
22	An Enhanced In Vivo Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC) Model for Quantification of Drug Metabolism Enzymes *. Molecular and Cellular Proteomics, 2015, 14, 750-760.	3.8	7
23	Cytochrome <i>b</i> <sub>5</sub> Is a Major Determinant of Human Cytochrome P450 CYP2D6 and CYP3A4 Activity In Vivo. Molecular Pharmacology, 2015, 87, 733-739.	2.3	30
24	The Hepatic Reductase Null (HRN <sup>â,,¢</sup> ) and Reductase Conditional Null (RCN) mouse models as suitable tools to study metabolism, toxicity and carcinogenicity of environmental pollutants. Toxicology Research, 2015, 4, 548-562.	2.1	13
25	Activation Status of the Pregnane X Receptor Influences Vemurafenib Availability in Humanized Mouse Models. Cancer Research, 2015, 75, 4573-4581.	0.9	23
26	Altered Protein <i>S</i> -Glutathionylation Identifies a Potential Mechanism of Resistance to Acetaminophen-Induced Hepatotoxicity. Journal of Pharmacology and Experimental Therapeutics, 2015, 355, 137-144.	2.5	25
27	Defining Human Pathways of Drug Metabolism In Vivo through the Development of a Multiple Humanized Mouse Model. Drug Metabolism and Disposition, 2015, 43, 1679-1690.	3.3	22
28	HDAC Inhibitors Increase NRF2-Signaling in Tumour Cells and Blunt the Efficacy of Co-Adminstered Cytotoxic Agents. PLoS ONE, 2014, 9, e114055.	2.5	21
29	Phenobarbital Induces Cell Cycle Transcriptional Responses in Mouse LiverÂHumanized for ConstitutiveÂAndrostane and Pregnane X Receptors. Toxicological Sciences, 2014, 139, 501-511.	3.1	60
30	Phenobarbital-Mediated Tumor Promotion in Transgenic Mice with Humanized CAR and PXR. Toxicological Sciences, 2014, 140, 259-270.	3.1	50
31	Epigenetic profiles as defined signatures of xenobiotic exposure. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2014, 764-765, 3-9.	1.7	53
32	<i>In Vivo</i> Regulation of Human Glutathione Transferase GSTP by Chemopreventive Agents. Cancer Research, 2014, 74, 4378-4387.	0.9	35
33	Cytochrome b5 and epoxide hydrolase contribute to benzo[a]pyrene-DNA adduct formation catalyzed by cytochrome P450 1A1 under low NADPH:P450 oxidoreductase conditions. Toxicology, 2014, 318, 1-12.	4.2	41
34	The Gerhard Zbinden memorial lecture. Toxicology Letters, 2002, 127, 3-17.	0.8	9
35	Role of the Conserved Phenylalanine 181 of NADPHâ^'Cytochrome P450 Oxidoreductase in FMN Binding and Catalytic Activityâ€. Biochemistry, 2001, 40, 13439-13447.	2.5	14
36	Determinants of specificity for aflatoxin B1-8,9-epoxide in Alpha-class glutathione S-transferases. Biochemical Journal, 1999, 339, 95-101.	3.7	11

3

#	Article	IF	CITATIONS
37	Crystal structure of the FMNâ€binding domain of human cytochrome P450 reductase at 1.93 à resolution. Protein Science, 1999, 8, 298-306.	7.6	78
38	1H, 15N and 13C NMR resonance assignment, secondary structure and global fold of the FMN-binding domain of human cytochrome P450 reductase. Journal of Biomolecular NMR, 1997, 10, 63-75.	2.8	30
39	Increased levels of alpha-class and pi-class glutathione S-transferases in cell lines resistant to 1-chloro-2,4-dinitrobenzene. FEBS Journal, 1993, 217, 671-676.	0.2	19